Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | LPL | P06858 | 2/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL3871182 | 0.74 | ENPP2 (0.44) | ENPP2KDM4EMGLL | |
| SCHEMBL9480117 | 0.73 | S100B (0.44) | KDM4ECA2CA1CA4CA5A | |
| SCHEMBL14396321 | 0.73 | ENPP2 (0.48) | ENPP2KDM4ECA2CA1LPL | |
| SCHEMBL204921 | 0.71 | ENPP2 (0.73) | ENPP2KDM4ECA2CA1LPL | |
| SCHEMBL55943 | 0.68 | TSHR (0.50) | ENPP2KDM4ECA2CA1LPL | |
| SCHEMBL11635138 | 0.65 | CA2 (0.46) | KDM4ECA2CA1TSHRCA4 | |
| SCHEMBL23493576 | 0.65 | ENPP2 (0.59) | ENPP2KDM4ECA2CA1TSHR | |
| SCHEMBL23169123 | 0.64 | TRPA1 (0.64) | KDM4ECA2CA1TSHR | |
| SCHEMBL22361789 | 0.64 | CA2 (0.48) | ENPP2KDM4ECA2CA1LPL | |
| SCHEMBL22361790 | 0.64 | CA2 (0.48) | ENPP2KDM4ECA2CA1LPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768966-B1 | COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7851637-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-1768966-A1 | COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | Infinity Pharmaceuticals, Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060025460-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
| WO-2006009869-A1 | COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025460-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | BCL3, BCL2, BCLAF1 | ENPP2 1029/4885KDM4E 2006/4885CA2 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.